Illustrative certificateNS-2026-06043

Nordicstar Analytical Sciences

CJC-1295 w/o DAC 10 MG

99.627%HPLC purity

Lot: GLZ-26-CJCND-1042
Measured content: 10.04 mg
Mass-spec identity: Confirmed
Endotoxin: <1.0 EU/mg
Tested: 15 Sep 2026

View Lab Report

Repair & Recovery

CJC-1295 w/o DAC

Q: Is CJC-1295 No DAC the same as Modified GRF (1-29)?

CJC-1295 No DAC is commonly used in the research-peptide market for the modified 29-amino-acid GHRH backbone also referred to as Modified GRF (1-29) or Mod GRF (1-29). Scientific and regulatory sources have documented inconsistent naming around CJC-1295 compounds, so distinguishing the No-DAC form from DAC-containing CJC-1295 is important.

Q: What does “No DAC” mean in CJC-1295 No DAC?

It means the peptide does not contain the additional albumin-binding DAC modification found in long-acting CJC-1295. The DAC-containing molecule was specifically engineered to associate with serum albumin and extend persistence.

Q: Does CJC-1295 No DAC have a 30-minute half-life?

A universal half-life should not be assigned to CJC-1295 No DAC based on values reported for other molecular forms. Persistence can vary according to the exact peptide structure and experimental conditions, and data from DAC-containing CJC-1295 should not be applied directly to the No-DAC form.

Modified GRF (1–29) · GHRH analogue research

$50.00USD / vialView COA

A pair saves 10%. A set of three saves 15%.

For laboratory research use only.
Not for human consumption or clinical use.

Compound details

Compound: CJC-1295 w/o DAC
Molecular formula: C152H252N44O42
Molecular weight: 3367.90 g/mol
Form: Lyophilized

Quality & documentation

The records shown here are illustrative. Request laboratory-issued documentation for your lot before ordering.

Lot: GLZ-26-CJCND-1042
HPLC purity: 99.627%
Measured content: 10.04 mg
Tested: 15 Sep 2026
Report: NS-2026-06043

View the 10 MG certificate

Our quality approach

Shipping & handling

Priority, tracked shipping within the United States, free on orders of $200 or more after savings. Add Priority dispatch at checkout to have your order packed first; Private Clients receive it on every order. Follow the product documentation for laboratory handling requirements.

Shipping information

Explore the research profile

CJC-1295 w/o DAC10 MG · Single

$50.00

01 / The compound

Understand
the starting point.

Modified GRF (1–29) · GHRH analogue research

CJC-1295 No DAC is a 29-amino-acid modified analog of the first 29 residues of growth hormone-releasing hormone (GHRH). In research-supply terminology, this peptide backbone is commonly referred to as Modified GRF (1-29) or Mod GRF (1-29).

The sequence contains four substitutions relative to native GHRH(1-29): D-Ala², Gln⁸, Ala¹⁵ and Leu²⁷. These substitutions distinguish the modified 29-amino-acid backbone from native GHRH(1-29) and are relevant to the compound's structural identity in laboratory research.

CJC-1295 No DAC should not be confused with the long-acting DAC-containing form of CJC-1295 studied in much of the published CJC-1295 literature.

02 / Research profile

The pathways.
The possibilities.

“No DAC” distinguishes this 29-amino-acid peptide from the long-acting CJC-1295 compound developed with an additional albumin-binding modification.

The published DAC form adds a modified lysine at the C-terminus that allows the peptide to bind to serum albumin. That albumin-binding design was used specifically to extend the compound's persistence. CJC-1295 No DAC does not contain that additional DAC modification.

Because the name CJC-1295 has been used inconsistently across scientific, regulatory and commercial sources, findings from DAC-containing CJC-1295 should not automatically be applied to CJC-1295 No DAC.

01 / Research focus

GHRH receptor activation

Related GHRH-analogue studies examine how modified peptide sequences interact with the GHRH receptor and influence downstream signaling under controlled experimental conditions.

02 / Research focus

Stability & enzymatic degradation

Research on related analogues examines structural changes intended to alter peptide persistence and susceptibility to enzymatic degradation. Findings must be matched to the exact molecular form rather than inferred from the CJC-1295 name alone.

Reading the evidence

Much of the published CJC-1295 literature uses an albumin-binding DAC modification. Those persistence data cannot be assigned directly to Modified GRF (1–29) without DAC; a universal half-life for the No-DAC form is not established by that comparison.

03 / Reference data

The details,
in plain sight.

Reference specifications describe a compound. The final lot documentation identifies the material supplied.

CJC-1295 w/o DAC reference specifications
Compound	CJC-1295 w/o DAC
Research area	Repair & Recovery
Molecular formula	C152H252N44O42
Molecular weight	3367.90 g/mol
Physical form	Lyophilized
Vial options	10 MG
Intended use	Laboratory research only

Variant amounts are nominal catalog quantities. They are not instructions for use.

04 / Quality & documentation

A number needs
its context.

How testing works

01 / Purity

What is in the sample?

HPLC separates components under a defined method. Read the reported percentage alongside the chromatogram, wavelength, integration method, and scope of the test.

02 / Identity

Is it the expected compound?

Mass spectrometry provides molecular-mass evidence. Identity and chromatographic purity answer different questions; one cannot stand in for the other.

03 / Traceability

Does the report match the vial?

Connect the product name, variant, lot identifier, report date, and issuing laboratory. A report is useful only when its sample can be linked to the material being reviewed.

Independent analysis

Every CJC-1295 w/o DAC lot is analyzed by Nordicstar Analytical Sciences for identity, content, and purity by HPLC with LC-MS confirmation. Each certificate carries a report number and verification key that can be checked at nordicstarlabs.com/verify. Research references below describe published science, not a certificate for a vial.

Read a COA with confidence

CJC-1295 w/o DAC lot certificates
Presentation	Lot	HPLC purity	Tested	Certificate
10 MG Current lot	`GLZ-26-CJCND-1042`	99.627%	15 Sep 2026	NS-2026-06043
10 MG	`GLZ-26-CJCND-758`	99.554%	21 Aug 2026	NS-2026-06157
10 MG	`GLZ-26-CJCND-658`	99.668%	08 Jul 2026	NS-2026-06158

05 / Storage & handling

Care for
the material.

Keep sealed research material protected from moisture, unnecessary light and temperature fluctuations. Use the storage conditions documented for the specific compound, formulation and lot.

Solution stability depends on solvent, concentration, container and experimental conditions. Use a validated laboratory protocol; a universal post-reconstitution shelf life is not established by the literature summaries.

Explore the handling guide

06 / Common questions

A little more
understanding.

Is CJC-1295 No DAC the same as Modified GRF (1-29)?

CJC-1295 No DAC is commonly used in the research-peptide market for the modified 29-amino-acid GHRH backbone also referred to as Modified GRF (1-29) or Mod GRF (1-29). Scientific and regulatory sources have documented inconsistent naming around CJC-1295 compounds, so distinguishing the No-DAC form from DAC-containing CJC-1295 is important.

What does “No DAC” mean in CJC-1295 No DAC?

It means the peptide does not contain the additional albumin-binding DAC modification found in long-acting CJC-1295. The DAC-containing molecule was specifically engineered to associate with serum albumin and extend persistence.

Does CJC-1295 No DAC have a 30-minute half-life?

A universal half-life should not be assigned to CJC-1295 No DAC based on values reported for other molecular forms. Persistence can vary according to the exact peptide structure and experimental conditions, and data from DAC-containing CJC-1295 should not be applied directly to the No-DAC form.

07 / Further reading